Cargando…

Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer

BACKGROUND: The expression of programmed cell death ligand 1(PD-L1) is related to the efficacy of immune checkpoint inhibitors on patients with non-small cell lung cancer (NSCLC), but tumor tissue (TT) samples are difficult to obtain, and initial TT samples are difficult to reflect the spatial-tempo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Yuxin, Wang, Ting, Lv, Xin, Li, Rutian, Yuan, Ling, Shen, Jie, Li, Yan, Yan, Tingting, Liu, Baorui, Wang, Lifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093656/ https://www.ncbi.nlm.nih.gov/pubmed/32256114 http://dx.doi.org/10.2147/CMAR.S245425

Ejemplares similares

The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC
por: Yang, Yang, et al.
Publicado: (2017)

Detection and monitoring of driver mutations by next‐generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation EGFR‐tyrosine kinase inhibitors
por: Shen, Xiaoyan, et al.
Publicado: (2017)

MicroRNA-200c Nanoparticles Sensitized Gastric Cancer Cells to Radiotherapy by Regulating PD-L1 Expression and EMT
por: Qian, Lingyu, et al.
Publicado: (2020)

Prognostic significance of PD‐L1 expression on cell‐surface vimentin‐positive circulating tumor cells in gastric cancer patients
por: Liu, Mengyuan, et al.
Publicado: (2020)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
por: Zhao, Yanjie, et al.
Publicado: (2020)

Development and validation of a nomogram for predicting survival in patients with malignant myofibroblastic tumor
por: Wang, Xiaolu, et al.
Publicado: (2023)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Combined delivery of salinomycin and docetaxel by dual-targeting gelatinase nanoparticles effectively inhibits cervical cancer cells and cancer stem cells
por: Wang, Qin, et al.
Publicado: (2021)

Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer
por: Acheampong, Emmanuel, et al.
Publicado: (2022)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer
por: Inoue, Yusuke, et al.
Publicado: (2016)

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
por: Kallergi, Galatea, et al.
Publicado: (2018)

Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma
por: Gu, Qianhui, et al.
Publicado: (2021)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR ‐mutant non‐small cell lung cancer
por: Lei, Si‐Yu, et al.
Publicado: (2023)

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
por: Zhang, Jie, et al.
Publicado: (2015)

Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer
por: Zhang, Lianru, et al.
Publicado: (2017)

Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
por: Yan, Chen, et al.
Publicado: (2022)

Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
por: Strati, Areti, et al.
Publicado: (2023)

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
por: Ji, Mei, et al.
Publicado: (2015)

Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma
por: Jiang, Yubo, et al.
Publicado: (2017)

Erratum to evaluation of PD-L1 expression on circulating tumour cells in small cell lung cancer
Publicado: (2022)

Novel silk fibroin nanoparticles incorporated silk fibroin hydrogel for inhibition of cancer stem cells and tumor growth
por: Wu, Puyuan, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
por: Zhu, Jue, et al.
Publicado: (2021)

Enhanced and Prolonged Antitumor Effect of Salinomycin-Loaded Gelatinase-Responsive Nanoparticles via Targeted Drug Delivery and Inhibition of Cervical Cancer Stem Cells
por: Wang, Qin, et al.
Publicado: (2020)

PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis
por: Shen, Xuxia, et al.
Publicado: (2021)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
por: Su, Chaoyue, et al.
Publicado: (2020)

Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer
por: Zhou, Qing, et al.
Publicado: (2023)

Recent advances in neoantigen vaccines for treating non‐small cell lung cancer
por: Su, Shu, et al.
Publicado: (2023)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
por: Li, Chuling, et al.
Publicado: (2019)

Comparison of PD‐L1 detection assays and corresponding significance in evaluation of diffuse large B‐cell lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

Targeting PD-L1 in non-small cell lung cancer using CAR T cells
por: Liu, Ming, et al.
Publicado: (2020)

Cell-Free MicroRNA Expression Profiles in Malignant Effusion Associated with Patient Survival in Non-Small Cell Lung Cancer
por: Wang, Tingting, et al.
Publicado: (2012)

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
por: Yang, Fang, et al.
Publicado: (2021)

Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy
por: Tong, Bing, et al.
Publicado: (2017)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
por: Shi, Wei, et al.
Publicado: (2023)

Case Report: Small intestinal metastatic breast cancer: A case report and literature review
por: Li, Yishan, et al.
Publicado: (2022)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
por: Nicolazzo, Chiara, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8apv1o253fdgmo919cp6kn4iph